Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema

Michael J. Elman, Lloyd Paul Aiello, Roy W. Beck, Neil M Bressler, Susan B Bressler, Allison R. Edwards, Frederick L. Ferris, Scott M. Friedman, Adam R. Glassman, Kellee M. Miller, Ingrid U. Scott, Cynthia R. Stockdale, Jennifer K. Sun

Research output: Contribution to journalArticle

Abstract

Objective: Evaluate intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone combined with focal/grid laser compared with focal/grid laser alone for treatment of diabetic macular edema (DME). Design: Multicenter, randomized clinical trial. Participants: A total of 854 study eyes of 691 participants with visual acuity (approximate Snellen equivalent) of 20/32 to 20/320 and DME involving the fovea. Methods: Eyes were randomized to sham injection + prompt laser (n=293), 0.5 mg ranibizumab + prompt laser (n=187), 0.5 mg ranibizumab + deferred (≥24 weeks) laser (n=188), or 4 mg triamcinolone + prompt laser (n=186). Retreatment followed an algorithm facilitated by a web-based, real-time data-entry system. Main Outcome Measures: Best-corrected visual acuity and safety at 1 year. Results: The 1-year mean change (±standard deviation) in the visual acuity letter score from baseline was significantly greater in the ranibizumab + prompt laser group (+9±11, P

Original languageEnglish (US)
JournalOphthalmology
Volume117
Issue number6
DOIs
StatePublished - Jun 2010
Externally publishedYes

Fingerprint

Triamcinolone
Macular Edema
Lasers
Visual Acuity
Retreatment
Ranibizumab
Information Systems
Randomized Controlled Trials
Outcome Assessment (Health Care)
Safety
Injections

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema. / Elman, Michael J.; Aiello, Lloyd Paul; Beck, Roy W.; Bressler, Neil M; Bressler, Susan B; Edwards, Allison R.; Ferris, Frederick L.; Friedman, Scott M.; Glassman, Adam R.; Miller, Kellee M.; Scott, Ingrid U.; Stockdale, Cynthia R.; Sun, Jennifer K.

In: Ophthalmology, Vol. 117, No. 6, 06.2010.

Research output: Contribution to journalArticle

Elman, MJ, Aiello, LP, Beck, RW, Bressler, NM, Bressler, SB, Edwards, AR, Ferris, FL, Friedman, SM, Glassman, AR, Miller, KM, Scott, IU, Stockdale, CR & Sun, JK 2010, 'Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema', Ophthalmology, vol. 117, no. 6. https://doi.org/10.1016/j.ophtha.2010.02.031
Elman, Michael J. ; Aiello, Lloyd Paul ; Beck, Roy W. ; Bressler, Neil M ; Bressler, Susan B ; Edwards, Allison R. ; Ferris, Frederick L. ; Friedman, Scott M. ; Glassman, Adam R. ; Miller, Kellee M. ; Scott, Ingrid U. ; Stockdale, Cynthia R. ; Sun, Jennifer K. / Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema. In: Ophthalmology. 2010 ; Vol. 117, No. 6.
@article{d2ac6368645945dfb147161d667a7b4a,
title = "Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema",
abstract = "Objective: Evaluate intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone combined with focal/grid laser compared with focal/grid laser alone for treatment of diabetic macular edema (DME). Design: Multicenter, randomized clinical trial. Participants: A total of 854 study eyes of 691 participants with visual acuity (approximate Snellen equivalent) of 20/32 to 20/320 and DME involving the fovea. Methods: Eyes were randomized to sham injection + prompt laser (n=293), 0.5 mg ranibizumab + prompt laser (n=187), 0.5 mg ranibizumab + deferred (≥24 weeks) laser (n=188), or 4 mg triamcinolone + prompt laser (n=186). Retreatment followed an algorithm facilitated by a web-based, real-time data-entry system. Main Outcome Measures: Best-corrected visual acuity and safety at 1 year. Results: The 1-year mean change (±standard deviation) in the visual acuity letter score from baseline was significantly greater in the ranibizumab + prompt laser group (+9±11, P",
author = "Elman, {Michael J.} and Aiello, {Lloyd Paul} and Beck, {Roy W.} and Bressler, {Neil M} and Bressler, {Susan B} and Edwards, {Allison R.} and Ferris, {Frederick L.} and Friedman, {Scott M.} and Glassman, {Adam R.} and Miller, {Kellee M.} and Scott, {Ingrid U.} and Stockdale, {Cynthia R.} and Sun, {Jennifer K.}",
year = "2010",
month = "6",
doi = "10.1016/j.ophtha.2010.02.031",
language = "English (US)",
volume = "117",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema

AU - Elman, Michael J.

AU - Aiello, Lloyd Paul

AU - Beck, Roy W.

AU - Bressler, Neil M

AU - Bressler, Susan B

AU - Edwards, Allison R.

AU - Ferris, Frederick L.

AU - Friedman, Scott M.

AU - Glassman, Adam R.

AU - Miller, Kellee M.

AU - Scott, Ingrid U.

AU - Stockdale, Cynthia R.

AU - Sun, Jennifer K.

PY - 2010/6

Y1 - 2010/6

N2 - Objective: Evaluate intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone combined with focal/grid laser compared with focal/grid laser alone for treatment of diabetic macular edema (DME). Design: Multicenter, randomized clinical trial. Participants: A total of 854 study eyes of 691 participants with visual acuity (approximate Snellen equivalent) of 20/32 to 20/320 and DME involving the fovea. Methods: Eyes were randomized to sham injection + prompt laser (n=293), 0.5 mg ranibizumab + prompt laser (n=187), 0.5 mg ranibizumab + deferred (≥24 weeks) laser (n=188), or 4 mg triamcinolone + prompt laser (n=186). Retreatment followed an algorithm facilitated by a web-based, real-time data-entry system. Main Outcome Measures: Best-corrected visual acuity and safety at 1 year. Results: The 1-year mean change (±standard deviation) in the visual acuity letter score from baseline was significantly greater in the ranibizumab + prompt laser group (+9±11, P

AB - Objective: Evaluate intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone combined with focal/grid laser compared with focal/grid laser alone for treatment of diabetic macular edema (DME). Design: Multicenter, randomized clinical trial. Participants: A total of 854 study eyes of 691 participants with visual acuity (approximate Snellen equivalent) of 20/32 to 20/320 and DME involving the fovea. Methods: Eyes were randomized to sham injection + prompt laser (n=293), 0.5 mg ranibizumab + prompt laser (n=187), 0.5 mg ranibizumab + deferred (≥24 weeks) laser (n=188), or 4 mg triamcinolone + prompt laser (n=186). Retreatment followed an algorithm facilitated by a web-based, real-time data-entry system. Main Outcome Measures: Best-corrected visual acuity and safety at 1 year. Results: The 1-year mean change (±standard deviation) in the visual acuity letter score from baseline was significantly greater in the ranibizumab + prompt laser group (+9±11, P

UR - http://www.scopus.com/inward/record.url?scp=77952779304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952779304&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2010.02.031

DO - 10.1016/j.ophtha.2010.02.031

M3 - Article

C2 - 20427088

AN - SCOPUS:77952779304

VL - 117

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 6

ER -